0809 GMT - Smith & Nephew's continuing strength in U.S. orthopedics is reassuring, RBC Capital Markets analyst Jack Reynolds-Clark says in a research note. The U.K. medical-technology company posted first-quarter revenue in line with consensus expectations, with underlying growth ahead of views albeit a greater-than-expected impact of currency fluctuations, the analyst says. As expected, the performance in China was a significant headwind in the quarter, the analyst adds. "The results demonstrate continued strength in U.S. Orthopaedics and Sports Medicine and incrementally de-risk expectations for the full year 2025," the analyst says. Shares are up 5.1% at 1,050.50 pence. (maitane.sardon@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 04:09 ET (08:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.